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Introduction {#sec1}
============

It is estimated that 17.8 million of 36.7 million people living with HIV in 2015 were women and girls of reproductive age (\>15 years).[@bib1] Widespread use of combined antiretroviral treatment (ART) has dramatically reduced rates of vertical transmission while improving maternal health and birth outcomes. However, rates of adverse birth outcomes--including preterm birth (PTB), small for gestational age (SGA), and stillbirth--remain higher among women and adolescents living with HIV (WLHIV) receiving ART than HIV-uninfected women.[@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11] There are few studies investigating the mechanisms associated with adverse birth outcomes in pregnant WLHIV. As the number of pregnant WLHIV having children increases,[@bib12] it is important to understand the disease processes underlying adverse birth outcomes that, in turn, may facilitate improved clinical management. Recently, HIV was identified as a risk factor for maternal vascular malperfusion in a population of South African women.[@bib13]

Robust placental function is essential for fetal growth and development. Vasculogenic processes in the first trimester regulate de novo formation and growth of blood vessels. Angiogenic processes beginning in the second trimester induce remodeling of the underlying placental architecture to allow for increased blood flow and surface area for nutrient exchange.[@bib14], [@bib15] Altered expression of angiogenic factors is associated with a number of complications in pregnancy including preeclampsia,[@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27] systemic lupus erythematosus and/or antiphospholipid antibodies,[@bib28] fetal growth restriction,[@bib22], [@bib29], [@bib30] preterm delivery,[@bib31] and spontaneous abortion/stillbirth,[@bib21], [@bib32], [@bib33] suggesting placental stress responses triggered by placental malperfusion can lead to systemic changes in angiogenic factors.[@bib34], [@bib35], [@bib36]

The vascular endothelial growth factor (VEGF) family of proteins, including placental growth factor (PlGF), are proangiogenic mediators that are synthesized by trophoblast, and endothelial cells of the placental villi. VEGF and PlGF bind VEGF receptor 1 (fms-like tyrosine kinase \[Flt\]-1) and VEGF binds VEGF receptor 2 on the endothelium to induce vascular proliferation, migration, and sprouting.[@bib14], [@bib37], [@bib38] Flt-1 can be alternatively spliced to generate the antiangiogenic protein soluble Flt (sFlt)-1.[@bib39] The angiopoietins (Ang) bind their cognate receptor, tyrosine-protein kinase Tie-2. Ang-1 induces maturation and stabilization of the vasculature while Ang-2 generally causes destabilization and induces angiogenesis.[@bib15] Soluble endoglin (sEng) is a soluble receptor of transforming growth factor (TGF)-β that binds TGF-β and reduces its bioavailability.[@bib40] sEng appears to inhibit the immunoregulatory actions of TGF-β and acts as an antiangiogenic factor in the placenta by inhibiting vascular permeability and nitric-oxide-mediated vasodilation.[@bib40], [@bib41]

Angiogenic processes in the placenta affect pregnancy, but there are limited data documenting these processes in the context of HIV infection and low-resource settings where rates of adverse birth outcomes are the highest. We hypothesize that alterations in angiogenic factors are associated with adverse birth outcomes in pregnant WLHIV. To test this hypothesis we longitudinally characterized circulating plasma levels of angiogenic proteins in a cohort of WLHIV initiated on ART.[@bib42] In this report we describe the kinetics of angiogenic factors over pregnancy, compare angiogenic factors between different ART regimens (efavirenz- vs lopinavir/ritonavir-based ART), and evaluate whether angiogenic factors predict adverse birth outcomes (spontaneous PTB, SGA, and stillbirth).

Materials and Methods {#sec2}
=====================

Ethics statement {#sec2.1}
----------------

Written informed consent was obtained from all participants. Ethical approval was received from Makerere University School of Medicine (Sept. 20, 2009; reference 2009-141); the Uganda National Council for Science and Technology; the University of California--San Francisco (Aug. 9, 2009; reference 10-02958); and the University Health Network (March 13, 2014; reference 14-7313-AE). This trial was registered: [ClinicalTrials.gov](http://ClinicalTrials.gov){#intref0010} (identifier: [NCT00993031](ctgov:NCT00993031){#intref0015}).

Study population {#sec2.2}
----------------

Plasma samples were collected from pregnant WLHIV participating in a randomized controlled trial of protease inhibitor vs nonnucleoside reverse transcriptase inhibitor--based ART in Tororo, Uganda, from 2009 through 2013.[@bib42] Participants were HIV-infected, ≥16 years of age, and pregnant (12-28 weeks of gestation by last menstrual period with confirmation by ultrasound). Eligibility for enrollment was not dependent on CD4 cell count. Patients were ineligible to participate if they had received ART (including any abbreviated monotherapy) or dual therapy with nevirapine in the last 24 months. Subjects received standard antenatal care according to Ugandan Ministry of Health Guidelines (<http://www.health.go.ug/docs/ucg_2010.pdf>). Blood pressure and urine protein was assessed at enrollment and routine antenatal visits. Participants on protease inhibitor--based ART received lopinavir/ritonavir (n = 166) and those on nonnucleoside reverse transcriptase inhibitor--based ART received efavirenz (n = 160). Socioeconomic status was assessed as described.[@bib43]

Laboratory assays {#sec2.3}
-----------------

Blood collection and laboratory work was performed at baseline and at all subsequent antenatal visits. Clinical tests included complete blood cell count and determination of CD4^+^/CD8^+^ T-lymphocyte subsets. Standardized assessments were completed at delivery including gestational age and birthweight (using an electronic scale).

Study outcomes {#sec2.4}
--------------

Women were eligible for inclusion in this secondary analysis if they had a singleton pregnancy with known birth outcome, and samples collected within 6 prespecified gestational age bins: 16-\<20, 20-\<24, 24-\<28, 28-\<32, 32-\<36, 36-\<37 weeks of gestation. The primary exposure was biomarker levels and the primary outcome was PTB (so samples were not tested \>36 weeks of completed gestation). PTB was defined as delivery \<37 weeks of gestation (ultrasound dated), SGA was defined using INTERGROWTH standards,[@bib44] and stillbirth defined as intrauterine fetal demise ≥20 weeks of gestation.

Enzyme-linked immunosorbent assays {#sec2.5}
----------------------------------

EDTA plasma samples were collected and stored at −80°C prior to testing. Samples were tested in Uganda using commercially available enzyme-linked immunosorbent assays (Duosets, R&D Systems, Minneapolis, MN) with the following ranges, dilution factors, and intraassay coefficients of variation: Ang-1 (313-20,000 pg/mL, 1:10, 5.6%); Ang-2 (93.8-6000 pg/mL, 1:20, 6.1%); sEng (250-16,000 pg/mL, 1:20, 7.4%); sFlt-1 (250-16,000 pg/mL, 1:5, 11.9%); PlGF (63.0-4000 pg/mL, 1:5, 8.1%), and VEGF (31-2000 pg/mL, 1:2). All testing was performed blinded to group and outcome.

Statistical analysis {#sec2.6}
--------------------

Statistical analysis was performed using STATA v14 (StataCorp, College Station, TX), R v3.2.1[@bib45] (R Foundation for Statistical Computing), and GraphPad Prism v6 (GraphPad Software Inc, La Jolla, CA) software. Descriptive statistics were calculated as n (%) and median (interquartile range). The χ^2^ and Fisher exact tests were used to compare categorical variables. Linear regression was used to assess whether biomarker levels changed over pregnancy. To assess the effect of gestational age on angiogenic factor concentrations between birth outcome groups, we used the lme4[@bib46] package in R[@bib45] to construct linear mixed effects (LME) models with random intercept and random slope, adapting the approach employed by Romero et al.[@bib32] For each biomarker and outcome, we constructed a null model with 4 fixed effects: the linear effect of gestational age, maternal age, body mass index (BMI), and gravidity. To make the intercept meaningful, the gestational age variable was shifted such that the lowest gestational age in our data set (the baseline samples) would be the intercept's x-value. We also included the interaction between gestational age and treatment arm, to control for the possibility that the treatment affected the biomarker's rate of change. Treatment arm was omitted as a main effect to constrain the groups to have the same intercept, as baseline differences between the (randomly allocated) groups would have been due to chance. In 2 additional models, we added the birth outcome as a fixed effect: an additive, no-interaction model and an interaction model. Both models were the same as the null but also included outcome as a main effect; and the interaction model further included the interaction between outcome and gestational age. For none of the biomarkers or birth outcomes did the interaction term significantly improve the model fit (*P* \> .05 for all). Therefore, the data favor the more parsimonious additive models. For models in which the groups had different intercepts, the fitted lines did not significantly converge or diverge over time. For random effects, all models included a by-participant intercept and by-participant slope for the effect of gestational age. The biomarker levels were transformed using the natural logarithm to stabilize their variance. Residual plots did not show any apparent deviation from homoscedasticity or normality. Statistical significance was assessed using likelihood ratio (LR) tests, which compared in a stepwise fashion the null model, the additive model, and the interaction model. As the PlGF values vary quadratically over time, we added a quadratic interaction term to the model, which significantly improved the model fit \[LR test, χ^2^(1) = 157.15, *P* \< .0001\].

Results {#sec3}
=======

Description of the study population {#sec3.1}
-----------------------------------

A total of 1115 plasma samples were evaluated from 326 women and adolescents ([Figure 1](#fig1){ref-type="fig"}). The demographic characteristics of the study population are presented in [Table 1](#tbl1){ref-type="table"}. The median age of women was 30 years with a median BMI at enrollment of 21.4 kg/m^2^. The majority of participants (n = 271, 83%) were multigravida. None of the participants were diagnosed with chronic hypertension, preeclampsia, or eclampsia during the study period. Adverse birth outcomes in the cohort were common with 18.1% (n = 59) of participants having a low-birthweight infant (compared to a national estimate of 12%[@bib47]), 16.9% (n = 55) spontaneous PTB, 25.6% (n = 81) SGA, and 2.8% (n = 9) stillborn. The median gestational age of stillbirth deliveries was 31 weeks of gestation. Cause of fetal demise was not ascertained. Malaria infection status and birth outcomes did not differ between participants receiving lopinavir/ritonavir compared to those receiving efavirenz ([Supplemental Table 1](#tblS1){ref-type="table"}).Figure 1Flow chart of maternal plasma samples processed by gestational age*ART*, antiretroviral therapy; *EFV*, efavirenz; *LPV/r*, lopinavir/ritonavir.*Conroy et al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017*.Table 1Descriptive characteristics of study populationCohort, n = 326DemographicsAge, y30 (26--33)BMI, kg/m^2^21.4 (19.9--23.0)Socioeconomic status, tertile 1111 (35.9) 2135 (43.7) 363 (20.4)Gestational age at enrollment, wk23.6 (19.6--27.9)Previous pregnancies 020 (6.1) 135 (10.7) 2271 (83.1)Laboratory characteristicsHemoglobin level, g/dL11.0 (10.2--11.8)White blood cell count, cells/mm^3^5050 (4200--6200)Platelet count, ×10^9^/L210 (173--252)CD4^+^ T-cell count, cells/mm^3^369 (271--504)HIV RNA load, log~10~ copies/mL4.2 (3.9--4.8)Delivery characteristicsGestational age delivery, wk38 (37--40)Birthweight, kg2890 (2670--3230)Preterm birth55 (16.9)Small for gestational age81 (25.6)Stillbirth9 (2.8)Placental malaria[a](#tbl1fna){ref-type="table-fn"}24 (8.7)[^2][^3][^4][^5]

Longitudinal changes in angiogenic factors over pregnancy {#sec3.2}
---------------------------------------------------------

There were no differences in angiogenic proteins by trial arm ([Supplemental Figure 1](#figS1){ref-type="fig"}), so subsequent analysis was conducted using the combined cohort. We plotted the longitudinal kinetics of angiogenic factors over pregnancy and observed declining levels of Ang-2 across gestation, and increasing levels PlGF, sFlt-1, and sEng (*P* \< .0001 for all) ([Figure 2](#fig2){ref-type="fig"}). There were no differences in circulating Ang-1 levels across gestation. Median plasma Ang-2 decreased from 6.6 ng/mL at 16-20 weeks to 2.5 ng/mL by 37 weeks of gestation. Median levels of sEng increased from 9.1-14.7 ng/mL and sFlt-1 increased from 1.9-6.4 ng/mL from 16-20 and 37 weeks of gestation ([Figure 2](#fig2){ref-type="fig"}). PlGF levels were 0.24 ng/mL at 16-20 weeks, peaked at 0.84 ng/mL at 28-32 weeks, and declined to 0.40 ng/mL by 37 weeks of gestation ([Figure 2](#fig2){ref-type="fig"}). VEGF-A levels were largely undetectable with 87% of samples having concentrations below the bottom standard of 31.3 pg/mL.Figure 2Angiogenic factors in HIV infected study participants receiving antiretroviral therapyScatter plot of plasma levels of angiogenic factors plotted according to gestational age of sample collection: **A**, placental growth factor (PlGF); **B**, soluble fms-like tyrosine kinase (sFlt)-1; **C**, soluble endoglin (sEng); **D**, angiopoietin (Ang)-2; and **E**, Ang-1. Line indicates best fit line with 95% confidence intervals.*Conroy et al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017*.

Relationship between angiogenic factors and immune status {#sec3.3}
---------------------------------------------------------

To determine whether angiogenic factors were associated with maternal health or immune status, we conducted nonparametric bivariate correlations comparing angiogenic proteins and enrollment laboratory tests. There were no differences between angiogenic proteins measured in the first gestational age bin (16-\<20 weeks of gestation) and enrollment hemoglobin, platelet count, viral load, or CD4 count (*P* \> .05 for all).

Relationship between angiogenic factors and birth outcomes {#sec3.4}
----------------------------------------------------------

LME modeling evaluated the longitudinal changes in angiogenic factor concentrations between birth outcome groups. The models adjusted for gestational age at venipuncture, maternal age, BMI, gravidity, and the interaction between treatment arm and gestational age ([Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}, and [Table S2](#tblS2){ref-type="table"}, [Table S3](#tblS3){ref-type="table"}, [Table S4](#tblS4){ref-type="table"}). Two angiogenic factors--sEng and PlGF--were associated with adverse birth outcomes. Significantly higher concentrations of sEng throughout gestation were found in study participants destined to deliver preterm \[LR test, χ^2^(1) = 12.28, *P* \< .0005\] ([Figure 3](#fig3){ref-type="fig"}, A) and in those destined to have stillbirths \[χ^2^(1) = 5.67, *P* \< .02\] ([Figure 3](#fig3){ref-type="fig"}, B, and [Table 2](#tbl2){ref-type="table"}). By contrast, significantly lower concentrations of PlGF throughout gestation were found in those destined to have SGA births \[χ^2^(1) = 7.89, *P* \< .005\] ([Figure 3](#fig3){ref-type="fig"}, C) and in those destined to have stillbirths \[χ^2^(1) = 21.59, *P* \< .0001\] ([Figure 3](#fig3){ref-type="fig"}, D, and [Table 3](#tbl3){ref-type="table"}). To show the natural variability of biomarkers over gestation among individual participants, we generated trellis plots for a random subset of participants with the fitted regression line from the LME model conditional on fixed effects only ([Supplemental Figure 2](#figS2){ref-type="fig"}, [Supplemental Figure 3](#figS3){ref-type="fig"}, [Supplemental Figure 4](#figS4){ref-type="fig"}, [Supplemental Figure 5](#figS5){ref-type="fig"}).Figure 3Antiangiogenic shift is associated with adverse birth outcomes in women living with HIV receiving antiretroviral therapyIndividual data points colored by birth outcome. Overlaid regression lines are from linear mixed effects models, fitted for subject with average values (conditional on fixed effects only).*AGA*, appropriate for gestational age; *PlGF*, placental growth factor; *PTB*, preterm birth; *sEng*, soluble endoglin; *SGA*, small for gestational age.*Conroy et al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017*.Table 2Linear mixed effect modelling of longitudinal changes in soluble endoglin and adverse birth outcomesPreterm birthStillbirthBetaSEBetaSEFixed terms(Intercept)2.137330.17602.127620.1788Birth outcome0.167450.04750.264590.1110Gestational age (shifted)0.040930.00300.040640.0030Maternal age--0.001020.0047--0.001540.0048Enrollment BMI--0.004550.0063--0.002970.0064Gravidity--0.012700.0109--0.010470.0111Gestational age: treatment arm interaction--0.005070.0025--0.004710.0026No. of subjects320320Observations10851085LR test against null modelχ^2^(1) = 12.282, *P* \< .0005χ^2^(1) = 5.6717, *P* \< .02[^6][^7][^8]Table 3Linear mixed effect modelling longitudinal changes in placental growth factor and adverse birth outcomesSmall for gestational ageStillbirthBetaSEBetaSEFixed terms(Intercept)--3.038170.6134--3.143400.5889Birth outcome--0.380940.1357--1.663800.3520Gestational age (shifted)0.362860.02640.368280.0259Gestational age (shifted) squared--0.013790.0010--0.014050.0010Maternal age0.010620.01630.008810.0156Enrollment BMI--0.009810.0218--0.008760.0208Gravidity0.061390.03790.075300.0359Gestational age: treatment arm interaction--0.003840.0087--0.004210.0085No. of subjects311320Observations10801104LR test against null modelχ^2^(1) = 7.892, *P* \< .005χ^2^(1) = 21.595, *P* \< .0001[^9][^10][^11]

Comment {#sec4}
=======

Principal findings of the study {#sec4.1}
-------------------------------

Angiogenic processes in the placenta are critical regulators of fetal growth, but there are limited data documenting these processes in low-resource settings where maternal infections are common. In this study we assessed longitudinal concentrations in angiogenic proteins in HIV-infected pregnant women and adolescents started on ART. There were no differences in angiogenic factors by treatment arm. All proteins except Ang-1 and VEGF-A were dynamically regulated over gestation. Ang-2 levels declined, while sFlt-1 and sEng increased over gestation, and PlGF increased up to 32 weeks of gestation and then declined. Altered expression of angiogenic factors was associated with spontaneous PTB, SGA, and stillbirth. These data suggest an early shift toward an antiangiogenic state is a common pathway associated with adverse birth outcomes in WLHIV, consistent with data from HIV-uninfected women.[@bib22], [@bib31], [@bib32], [@bib34], [@bib48], [@bib49], [@bib50] Placental malaria was uncommon in this study due to the distribution of insecticide-treated bed nets and daily prophylaxis with trimethoprim-sulfamethoxazole.

Comparison with previous studies {#sec4.2}
--------------------------------

We evaluated 1115 plasma samples collected from 326 women and adolescents between 16-\<37 weeks of gestation. We compared our findings directly to results from women enrolled in a clinical trial receiving calcium supplementation in pregnancy with longitudinal assessment of sFlt-1, PlGF and VEGF,[@bib16] and sEng[@bib19] between 8-42 weeks of gestation.[@bib51] Both sFlt-1 and sEng levels increased over pregnancy starting at 24-28 weeks of gestation. While levels of sFlt-1 increased 3-fold over the third trimester, levels of sEng reached a plateau by 32-26 weeks of gestation. PlGF levels increased in early pregnancy, peaked between 28-32 weeks of gestation, and declined. Our results were consistent with those from the calcium trial suggesting temporal regulation of angiogenic factors is tightly controlled across pregnancy. In both studies, VEGF was measured but was undetectable in the majority of samples.

Despite their important regulatory role in placental vascular development, data on Ang kinetics in pregnancy are limited. Our observations are consistent with a report of decreased placental Ang-2 messenger RNA over pregnancy.[@bib14] Placental expression of Ang-2 messenger RNA is strongly correlated with circulating Ang-2 protein levels.[@bib14] Our results are further supported by a study examining plasma Ang levels between 10-37 weeks of gestation where Ang-2 levels decreased and Ang-1 remained the same across gestation.[@bib52] Collectively these data demonstrate the Ang-Tie-2 axis is dynamically regulated over pregnancy.

There are limited data on the impact of maternal HIV infection on expression of angiogenic factors. Lower PlGF levels have been reported in pregnant WLHIV in South Africa[@bib53]; however, the sample size was small (n = 27 HIV-uninfected, n = 31 WLHIV), and samples were collected a week later in WLHIV. Other studies examining angiogenic factors in nonpregnant individuals infected with HIV have shown increases in the Ang-2:Ang-1 ratio associated with acute HIV infection, and decreased Ang-1 in chronic disease.[@bib54] In HIV-infected Kenyan women with advanced infection, Ang-2 levels decreased and Ang-1 levels increased following the initiation of ART.[@bib55] On a cellular level, HIV-infected cells release transactivator of transcription, which accumulates on and is taken up by endothelial cells where it acts in synergy with VEGF-A to modify the cytoskeletal structure of endothelium.[@bib56], [@bib57]

There have been a number of studies investigating the relationship between placental angiogenesis, vascular remodeling, and stillbirth. In a study of 22 unexplained stillbirths and 44 age-matched live-born controls, stillbirth was associated with increased placental microvascular density, vasculopathy, and increased vascular permeability,[@bib58] suggesting increased vascular remodeling in terminal stillbirth placentae. In contrast, in 1269 singleton women with samples collected between 30-34 weeks of gestation, a low PlGF/sFlt-1 ratio was associated with stillbirth.[@bib21] Levels of sFlt-1 and sEng in the highest quartile of amniotic fluid were associated with increased odds of stillbirth in women with unexplained fetal death.[@bib23] In a longitudinal nested case-control study of women with a fetal death compared to those with an appropriate-for-gestational-age term delivery, the first trimester (weeks 7-11) was characterized by a proangiogenic phenotype (low sFlt-1, low sEng, high PlGF) and this shifted in favor of an antiangiogenic phenotype over the second and third trimester (between 23-41 weeks of gestation).[@bib32] Another cohort showed low sFlt-1 and PlGF levels in the first trimester were associated with spontaneous abortion.[@bib33] Our data support and extend the hypothesis that an antiangiogenic state in the second and third trimester is associated with subsequent stillbirth with lower PlGF and higher sEng levels. As the placental vascular network undergoes continual growth and remodeling, it requires the coordinated regulation of angiogenic factors in a spatial, temporal, and quantitative manner. Additional studies are needed to assess how temporal changes in angiogenic factors during pregnancy relate to the vascular phenotype observed in the placenta at delivery.

Beginning in the second trimester the placenta undergoes a continuous process of sprouting angiogenesis, intercalated growth, and intussusception. This remodeling allows for increased placental volume and surface area for nutrient exchange to support the rapidly growing fetus. Dysregulation of the pathways that mediate these processes midpregnancy may result in preterm delivery or fetal growth restriction if the placenta cannot support this rapid growth. Relative increases in sEng levels across gestation were associated with spontaneous PTB in this cohort, supporting the hypothesis that an antiangiogenic environment can contribute to premature birth.[@bib48], [@bib49] Likewise, reduced PlGF across gestation was associated with SGA, consistent with previous literature linking PlGF to placental and fetal growth and development.[@bib30], [@bib50]

Strengths and weaknesses {#sec4.3}
------------------------

This study has several strengths including ultrasound-confirmed gestational dating and frequent blood sampling. Despite routine clinical monitoring over pregnancy including monthly blood pressure and proteinuria assessments, no women in this cohort developed preeclampsia. This study is the first to present detailed kinetics data from a low-resource setting where the burden of disease is greatest, but for which we have the least amount of data. The lack of an HIV-uninfected comparison group in this study is a limitation that prevents us from discussing the generalizability of the findings or the relative impact of maternal HIV infection. While we did not observe any changes in angiogenic factor expression by treatment arm, CD4 count, or HIV-1 RNA viral load at enrollment, additional studies are needed to delineate the role of HIV-1 infection on the expression of angiogenic factors to determine whether infection itself modifies also the risk of adverse birth outcomes through dysregulated angiogenesis.

Research and clinical implications {#sec4.4}
----------------------------------

This study was conducted in a rural area of southeastern Uganda where the low incidence of preeclampsia is consistent with clinical reports from the region. While the reason for this is unknown, we speculate that a relative absence of risk factors for preeclampsia, including nulliparity, coupled with lower weight gain over gestation contributed to a lower risk of preeclampsia.[@bib59] The median weekly weight gain in the study was 0.2 kg with nearly 20% of women gaining no weight over the study period.[@bib60] Additional studies are needed to validate these findings in HIV-infected women and in populations where preeclampsia is more common to ascertain the generalizability of these findings, and whether early assessment of angiogenic markers may have utility in identifying high-risk pregnancies.

Conclusions {#sec4.5}
-----------

Early changes in angiogenic proteins may have predictive utility in identifying women at risk of adverse birth outcomes in WLHIV receiving ART. While these findings need to be prospectively validated, early identification of women at increased risk of adverse birth outcomes may facilitate enhanced monitoring and referral to health care facilities equipped to manage high-risk pregnancies ([Video](#mmc1){ref-type="supplementary-material"}).

Appendix {#appsec1}
========

Supplemental Figure 1Longitudinal changes in angiogenic factors by treatment armScatter plot of plasma levels of angiogenic factors plotted by treatment arm with nonnucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy (ART) in red and protease inhibitor (PI)-based ART in blue. Biomarkers plotted according to gestational age of sample collection: **A**, placental growth factor (PlGF); **B**, soluble fms-like tyrosine kinase (sFlt)-1; **C**, soluble endoglin (sEng); **D**, angiopoietin (Ang)-2; and **E**, Ang-1. Line indicates best fit line with 95% confidence intervals.*Conroy et al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017*.Supplemental Figure 2Representative plots of soluble endoglin (sEng) levels over gestation in participants destined to have preterm or term deliveryTrellis plots of 60 randomly selected subjects (n = 30 term, n = 30 preterm). Solid line depicts fitted regression line from linear mixed effect model (conditional on fixed effects only).*Conroy et al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017*.Supplemental Figure 3Representative plots of soluble endoglin (sEng) levels over gestation in participants destined to have livebirth or stillbirth infantTrellis plots of 18 randomly selected subjects (n = 9 livebirth, n = 9 stillbirth). Solid line depicts fitted regression line from linear mixed effect model (conditional on fixed effects only).*Conroy et al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017*.Supplemental Figure 4Representative plots of placental growth factor (PlGF) levels over gestation in participants destined to have small-for-gestational-age (SGA) or appropriate-for-gestational-age (AGA) infantTrellis plots of 60 randomly selected subjects (n = 30 AGA, n = 30 SGA). Solid line depicts fitted regression line from linear mixed effect model (conditional on fixed effects only).*Conroy et al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017*.Supplemental Figure 5Representative plots of placental growth factor (PlGF) levels over gestation in women destined to have livebirth or stillbirth infantTrellis plots of 18 randomly selected subjects (n = 9 livebirth, n = 9 stillbirth). Solid line depicts fitted regression line from linear mixed effect model (conditional on fixed effects only).*Conroy et al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017*.Table S1Descriptive characteristics of the study population by ART treatment armBaseline CharacteristicTreatment Arm*P* ValueEfavirenz-Based ART, n=160Lopinavir/ritonavir -Based ART, n=166Age (years)30 \[26, 33\]29.2 ± 5.30.623BMI (kg/m^2^)21.2 \[19.6, 22.9\]21.6 \[20.2, 23.2\]0.074Socioeconomic status (tertile)0.611 154 (36.2)57 (35.6) 268 (45.6)67 (41.9) 327 (18.1)36 (22.)Gestational age enrolment (weeks)23.6 \[19.7, 27.6\]23.5 \[19.4, 27.0\]0.711Previous pregnancies 013 (8.3)7 (4.2)0.275 115 (9.6)20 (12.1) ≥2132 (82.2)139 (83.6)Hemoglobin level (g/dL)11.0 \[10.2, 11.8\]11.1 \[10.2, 11.7\]0.855White blood cell count (cells/mm^3^)4900 \[4100, 6100\]5200 \[4300, 6400\]0.134Platelet count (x10^9^/L)218.0 \[177.5, 255.5\]201.0 \[167.0, 239.5\]0.080CD4+T-cell count (cells/mm^3^)373.0 (269.3-497.8)368.0 (280.5-507.5)0.575HIV RNA load (log~10~copies/mL)4.286 \[3.427, 4.837\]4.097 \[3.328, 4.755\]0.468**Outcome Characteristics**Gestational age delivery (weeks)39 (37-40)38 (37-39)0.061Birth weight (kg)2910 (2680-3240)2880 (2650-3210)0.503Preterm birth24 (15.0)31 (18.7)0.376Small-for-gestational age44 (27.2)37 (23.9)0.502Stillbirth4 (2.5)5 (3.0)1.000Placental malaria[1](#tblS1fn1){ref-type="table-fn"}14 (10.2)10 (7.1)0.363[^12][^13][^14]Table S2Linear mixed effects models of angiogenic markers and preterm birthAng-1Ang-2sFlt-1PlGFsEngBetaSEBetaSEBetaSEBetaSEBetaSE**Fixed Terms**(Intercept)2.134790.44452.175190.3960−0.435200.5145−3.269560.61192.137330.1760Preterm0.133870.1206−0.158450.10680.179020.1499−0.161960.16170.167450.0475Gestational age (shifted)−0.008440.0064−0.063470.00530.154260.00940.369990.02600.040930.0030Gestational age (shifted) squared−0.014070.0010Maternal age−0.003040.0120−0.014710.0109−0.003750.01320.006460.0162−0.001020.0047Enrolment BMI0.002970.01610.006550.0144−0.020360.0181−0.002980.0216−0.004550.0063Gravidity−0.024310.02770.019200.0253−0.024790.03080.081500.0375−0.012700.0109Gestational age: treatment arm interaction0.001320.0062−0.002900.00630.004370.0058−0.004020.0086−0.005070.0025Number of subjects320312320320320Observations11041049110411041085LR Test against Null Modelχ^2^(1) = 1259, p \> 0.05χ^2^(1) = 2.233, p \> 0.05χ^2^(1) = 1.444, p \> 0.05χ^2^(1) = 1.020, p \> 0.05χ^2^(1) = 12.282, p \< 0.0005\*[^15]Table S3Linear mixed effects models of angiogenic markers and small-for-gestational ageAng-1Ang-2sFlt-1PlGFsEngBetaSEBetaSEBetaSEBetaSEBetaSE**Fixed Terms**(Intercept)2.141910.45592.132460.4024−0.394290.5229−3.038170.61342.126740.1820Stillbirth−0.007120.10280.133170.0920−0.033390.1140−0.380940.1357−0.001890.0408Gestational age (shifted)−0.007600.0064−0.062470.00530.151380.00950.362860.02640.040840.0030Gestational age (shifted) squared−0.013790.0010Maternal age−0.003740.0124−0.015080.0111−0.003390.01360.010620.0163−0.000600.0049Enrolment BMI0.003010.01650.004890.0147−0.019530.0185−0.009810.0218−0.004000.0066Gravidity−0.019630.02870.025060.0259−0.024510.03190.061390.0379−0.011340.0114Gestational age: treatment arm interaction0.001130.0063−0.002960.00640.005190.0059−0.003840.0087−0.004450.0026Number of subjects311303311311311Observations10801025108010801061LR Test against Null Modelχ^2^(1) = 0.0, p \> 0.05χ^2^(1) = 2.128, p \> 0.05χ^2^(1) = 0.0878, p \> 0.05χ^2^(1) = 7.892, p \< 0.005\*χ^2^(1) = 0.0025, p \> 0.05[^16]Table S4Linear mixed effects models of angiogenic markers and stillbirthAng-1Ang-2sFlt-1PlGFsEngBetaSEBetaSEBetaSEBetaSEBetaSE**Fixed Terms**(Intercept)2.140070.44682.200690.3979−0.408890.5146−3.143400.58892.127620.1788Stillbirth0.016160.2756−0.247060.2320−0.340660.3784−1.663800.35200.264590.1110Gestational age (shifted)−0.008870.0064−0.063290.00530.152780.00930.368280.02590.040640.0030Gestational age (shifted) squared−0.014050.0010Maternal age−0.003090.0120−0.014860.0109−0.003620.01320.008810.0156−0.001540.0048Enrolment BMI0.003690.01610.004800.0145−0.019590.0181−0.008760.0208−0.002970.0064Gravidity−0.023310.02780.018850.0253−0.023590.03080.075300.0359−0.010470.0111Gestational age: treatment arm interaction0.001490.0062−0.003160.00630.004270.0058−0.004210.0085−0.004710.0026Number of subjects320312320320320Observations11041049110411041085LR Test against Null Modelχ^2^(1) = 0.0045, p \> 0.05χ^2^(1) = 1.129, p \> 0.05χ^2^(1) = 0.819, p \> 0.05χ^2^(1) = 21.595, p \< 0.0001\*χ^2^(1) = 5.6717, p \< 0.02\*[^17]
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